Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Subbiah, Vivek; A. Cassier, Philippe; Siena, Salvatore; Garralda, Elena; Paz‐Ares, Luis; Garrido, Pilar; Nadal, Ernest; Vuky, Jacqueline; Lopes, Gilberto; P. Kalemkerian, Gregory; W. Bowles, Daniel; Seetharam, ­Mahesh; Chang, Jianhua; Zhang, Hui; Green, Jennifer; Zalutskaya, Alena; Schüler, Martin; Fan, Yun; Curigliano, Giuseppe

doi:10.1038/s41591-022-01931-y

Public

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Published in Nature Medicine • Aug 1, 2022

Authors:

Vivek Subbiah

Philippe A. Cassier

Salvatore Siena

Abstract

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors. Twenty-nine patients with 12 diffe...

Subject

Medicine

Internal medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!